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Sodium–glucose cotransporter 2 inhibition:
cardioprotection by treating diabetes—a
translational viewpoint explaining its potential
salutary effects
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Department of Cardiology, University of Groningen, University Medical Center Groningen (UMCG), AB43, Antonius Deusinglaan 1, Hanzeplein 1, 9713GZ Groningen,
The Netherlands
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Diabetes is a growing epidemic worldwide characterized by an elevated concentration of blood glucose, associated with a high incidence of
cardiovascular disease and mortality. Although in general reduction of hyperglycaemia is considered a therapeutic goal, hypoglycaemic ther-
apies do not necessarily reduce cardiovascular mortality and may even aggravate cardiovascular risk factors, such as body weight. A new class of
antidiabetic drugs acts by inhibition of the sodium–glucose cotransporter 2 (SGLT2), which (partially) prevents reabsorption of glucose from
the renal filtrate. The induction of glucose excretion via the urine (glycosuria) was turned into an effective strategy to reduce blood glucose.
Ancillary advantages are the caloric and volumetric loss and thereby the reduction of body weight and blood pressure. Additionally, SGLT2
inhibition has been suggested to exert direct cardioprotective effects by the reduction of cardiac fibrosis, inflammation, and oxidative stress.
This article summarizes the functional consequences of SGLT2 inhibition on the diabetic and hyperglycaemic organism. We especially focused
on the effects on the kidney and the cardiovascular system as described in experimental studies. The interesting observations in experimental
studies may extend to clinical medicine, as a recent trial reported a decrease in heart failure outcomes in patients at high cardiovascular risk. In
conclusion, SGLT2 inhibition represents a novel treatment, which might be a promising target not only to (further) reduce blood glucose but
also to target other cardiovascular risk factors. More research and long-term follow-ups will reveal the specific influence of SGLT2 inhibition on
the circulatory system and cardiovascular outcomes.
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Introduction
Diabetes is a growing epidemic due to population growth, ageing,
urbanization, and westernization.1,2 Hereby, the burden of diabetes
translates into substantial social and economic problems.1 Cardio-
vascular disease (CVD) is very common in diabetic subjects and is
the most frequent cause of death in these patients.3 – 5 Diabetic
hyperglycaemia causes a number of microvascular and macrovascu-
lar complications (Figure 1).4,6,7 The alleviation of hyperglycaemia,
often by oral antidiabetic drugs, leads to improvement of insulin sen-
sitivity, b-cell function, and reduction of microvascular complica-
tions such as retinopathy, neuropathy, and nephropathy.4,6,8 – 11
Several oral antidiabetic drugs are in use, including metformin,
sulphonyl urea derivatives, dipeptidyl peptidase-4 (DPP-4)
inhibitors, and thiazolidinediones. However, current therapies tar-
geted to reduce hyperglycaemia tend to lose their effectiveness
over time and are associated with negative side effects, including
weight gain and hypoglycaemia.1,12,13 Furthermore, standard anti-
hyperglycaemic treatments do not necessarily confer full protection
against CVDs, such as coronary artery disease (CAD), stroke, and
peripheral vascular disease as shown in several large, long-term out-
come studies,11,13– 17 partially explained by the risk at hypoglycaem-
ic events. Furthermore, in order to effectively reduce cardiovascular
(CV) events in diabetic patients, co-morbidities such as obesity,
hypertension, and hypercholesterolaemia must be co-targeted, in
conjunction to the maintenance of glycaemic control.4,18
Recently, a new class of drugs, the sodium–glucose cotranspor-
ter 2 (SGLT2) inhibitors, was introduced, which reduce blood
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glucose by (partially) blocking its reabsorption in the kidneys leading
to glucose excretion via the urine.12 Glucose reabsorption is mainly
orchestrated by the SGLT2.12,19,20 A number of well-tolerated
SGLT2 inhibitors are currently being tested in clinical trials as
glucose-lowering medication.2,19,21 – 23 SGLT2 inhibition might
have neutral or positive effects on CV risk factors by volume deple-
tion and caloric loss (Figure 1).22 Additionally, because the mode of
action does not influence insulin secretion or sensitivity, a larger
number of diabetic patients can be targeted, possibly also patients
with type 1 diabetes mellitus (T1DM).24
Although short-term outcomes on safety and efficacy of SGLT2
inhibition to target hyperglycaemia are promising, the long-term
outcomes on CVD are presently unclear.25 This review will sum-
marize the physiology of SGLT2 inhibition, and clinical and
pre-clinical data are collected in an effort to clarify the impact of
SGTL2 inhibition on CV risk factors and outcomes.
Renal glucose reabsorption by
sodium–glucose cotransporter in
diabetes
The kidneys are vital organs in regulating the glucose balance by
gluconeogenesis, filtration, and reabsorption.12,26,27 When blood
glucose is at normal levels, the kidneys filter 180 g of glucose
per day.27 Virtually all glucose filtered in the glomerulus is
reabsorbed and as a result (almost) no glucose is excreted in the ur-
ine (,0.5 g/day).26,27 Glucose transport is bound to a maximum
threshold (TmG).
28,29 Glycosuria will occur whenever this max-
imum is exceeded.22,29
Renal glucose control is generally disturbed in diabetes, which
further exacerbates hyperglycaemic conditions.26 Gluconeogenesis
in the diabetic kidney can be increased up to 300%, while diabetic
glomerular filtration rate (GFR) may increase or exceed up to
120 mL/min/1.73 m2, leading to reabsorption of glucose of
300 g/day.26 – 28 Additionally, TmG is increased in both T1DM
and T2DM.28,29 By targeting the function of SGLT in the kidneys,
theoretically TmG could decrease as well as the amount of glucose
reabsorption, which may benefit the severity of disease.
Distribution and function of
sodium–glucose cotransporters
SGLTs utilize the electrical gradient of sodium to transport glucose
over cellular membranes.30 They habitually collaborate with glucose
transporters (GLUTs) to facilitate glucose transport into the inter-
stitial fluid after reabsorption (by SGLT) from the lumen.12 Most
SGLTs (1, 2, and 4–6) are transcribed from the SLC5 gene.
SGLT1 and SGLT2 are the predominant transporters with variable
expression in several tissues (Table 1).20
Both SGLT1 and SGLT2 are expressed in the kidney (Figure 2).32,33
SGLT2 is a ‘low-affinity high-capacity’ transporter, due to a very
condensed expression in the S1 segment of the proximal tubule
Figure 1 The importance of diabetes for hyperglycaemia and the circulatory system. Sodium–glucose cotransporter 2 inhibition decreases
sodium–glucose reabsorption, which will lead to a decrease in hyperglycaemia (red arrows) and positively affects body weight and blood pressure.
ROS, reactive oxygen species; CKD, chronic kidney disease; CAD, coronary artery disease.
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of the kidney.33,34 SGLT1 is a ‘high-affinity low-capacity’ transporter
expressed in the more distal segment (S3).33,34 The SGLT2 transport-
er is considered responsible for 90% of all glucose reabsorption,
confirmed by studies using kidney-specific depletion of the SGLT2
gene.22,32,34 SGLT1 primarily exerts a role in glucose absorption
of the small intestine.31,35 SGLT1 may also play a role in glucose re-
absorption in the late proximal tubule in the event that the function
of SGLT2 is comprised.12,20,36 However, no compensatory role of
SGLT1 has been described during SGLT2 inhibition.37 Nevertheless,
the maximum degree of inhibition of glucose reabsorption does not
exceed 30–50%.38 Specific SGLT2 inhibition is therefore antici-
pated to result in substantial glycosuria, leading to a decrease in plas-
ma glucose, with a low risk for hypoglycaemic events.39
Renal glucose transport
in hyperglycaemia
SGLT2 works at 50% capacity and becomes saturated when the glu-
cose concentration exceeds .35 mM.20 However, SGLT expres-
sion levels are increased in diabetes. A study in Akita (T1DM)
mice and STZ-induced diabetic rats has shown that SGLT2 expres-
sion in the renal membrane increases in DM, and SGTL1 expression
was decreased in comparison with their healthy littermates.40 Fur-
thermore, others studies reported an increase in SGLT2 synthesis in
hyperglycaemic conditions and increased SGLT2 and GLUT2 ex-
pression on isolated proximal tubular cells from fresh urine in hu-
mans.41,42 These findings may correspond to the increased level
of TmG and glucose reabsorption in diabetic patients.
27,42
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1 Tissue distribution and substrate for sodium–glucose cotransporters 1 and 231
Transport Substrate Distribution
SGLT1 (SLC5A1) Glucose, galactose, mannose Intestine, trachea, kidney, heart, brain, testis and prostate
SGLT2 (SLC5A2) Glucose (and galactose, not transported) Kidney, brain, liver, thyroid, muscle, and heart
Figure 2 Regulation of glucose transport by the kidney. The left panel depicts glucose transport (black arrows). Most glucose is reabsorbed in
the S1 segment by sodium–glucose cotransporter 2. The top right picture shows how the sodium–glucose cotransporter 2 transporter binds one
glucose molecule and one sodium ion to transport glucose from the tubular lumen. Here, glucose transporter 2 pumps glucose into the interstitial
fluid. Sodium–glucose cotransporter 1 binds one glucose and two sodium molecules where it co-operates with glucose transporter 1. Sodium is
actively pumped out of the cell by the Na+/K+ pump. SGLT, sodium–glucose cotransporter; GLUT, glucose transporter.
246 A.E. de Leeuw and R.A. de Boer
Downloaded from https://academic.oup.com/ehjcvp/article-abstract/2/4/244/2197138
by University of Groningen user
on 06 December 2017
Sodium–glucose cotransporter 2
deficiency
Transgenic mouse models have been created by disruption of the
SLC5A gene.43,44 It has been shown that the sweet pee model of
Lee et al., when diabetes is induced, has improved glycaemic control,
although the mortality rate was increased in these groups, possibly
due to kidney failure.43 Experiments by Jurczak et al., who crossed
SGLT2/2 with ob/ob mice, showed that SGLT deficiency was pro-
tective against the development of T2DM.44 These results indicate
that SGLT2 depletion leads to improved glycaemic control during
hyperglycaemic conditions.
Human familial renal glycosuria is a rare, hereditary condition
which may be caused by mutations in the SCL5A2 gene, leading to
different expression levels of SGLT2.45– 47 Patients with such muta-
tions are characterized by excretion of glucose in the urine varying
from 1 to 170 g/day, yet accompanied with normal plasma glucose
concentrations.2,31,45 Patients with full depletion of SGLT2, how-
ever, are diagnosed with massive glycosuria, sometimes combined
with natriuresis and polyuria.46– 48 In these patients, no clinical or re-
nal complications have been reported, which may prompt the con-
sideration that glycosuria is a benign condition, and may be suitable
as a treatment option for diabetic patients.31,45 – 49 However,
the number of patients studied was very low, while it cannot be
excluded that other genes compensate in inherited conditions.
Glycaemic effects of sodium–
glucose cotransporter 2 inhibition
Phlorizin is a naturally occurring SGLT inhibitor, which is present in
fruit trees. It has been evaluated for its glucose-lowering effects, and
pre-clinical research showed promising data.8,40,50 However, phlor-
izin turned out to be non-selective, which rendered it clinically not
useful due to severe gastrointestinal side effects, such as osmotic
diarrhoea.12,43 An ideal target for reducing hyperglycaemia by indu-
cing glycosuria should be selective, safe, and well tolerated.12,23
Later, specific SGLT2 inhibitors were developed and currently
multiple SGLT2 inhibitors are under investigation in clinical trials.
Examples are ipragliflozin,51,52 empagliflozin,53 remigliflozin,54 and
tofogliflozin.55 Moreover, some SGLT2 inhibitors are already regis-
tered treatments for T2DM, such as empagliflozin, canagliflozin
(USA),21,22,53,56 and dapagliflozin (Europe).21–23,53,57,58 These drugs
were all tested and showed to have high affinity for SGLT2, low af-
finity for SGLT1, good bioavailability, and slow physical breakdown,
allowing a (once) daily oral dose administration.53
Most clinical research has been performed on patients with T2DM
(Table 2). Here, it has been reported that chronic SGLT2 inhibition
for 24 weeks lowers the percentage of plasma glycated haemoglobin
(HbA1c) levels by 0.5–2.5% depending on the dose, drug, and the
baseline HbA1c levels.2,19,53,76 –80 For example, in patients with late-
stage diabetes and thereby higher HbA1c (diagnosed for over 11–
19 years), HbA1c decreased to an identical level, but twice as fast
compared with other glucose-lowering drugs.81
Animal studies with SGLT2 inhibition have shown that fasting
plasma glucose (FPG) was reduced up to 50% in hyperglycaemic
or diabetic conditions, while there was no change in normoglycaem-
ic conditions,36,54,82 suggestive for a low risk of hypoglycaemic
events. Patient studies have shown a decrease in FPG from 21.0
to 23.3 mmol/L after 12 weeks treatment with either dapagliflozin,
empagliflozin, or canagliflozin, which remained constant up to 72
weeks.59,60,63,71,73,78,83,84 In comparison, patients with inadequate
control of hyperglycaemia showed less of a decline, of even an in-
crease in FPG when treated with a placebo next to their normal
treatment.59,60,71,84 These results indicated a quick decline in plasma
glucose, which plateaus to a steady decrease after a longer period of
time. Furthermore, SGLT2 inhibition appears to be a valuable
add-on therapy in inadequately controlled patients to further
reduce hyperglycaemia and to improve long-term stability of target
values.61,63,83,85 – 89 Additionally, increasing doses of insulin to re-
main a euglycaemic state were no longer required during SGLT2 in-
hibition, and therefore may improve insulin resistance and prevent
negative side effects of insulin, such as increases in body weight.90
Other beneficial findings on SGLT2 inhibition are improvement
of pancreatic b-cell function concerning glucose sensitivity,91 cell
mass and overall function,91 – 95 and improvement in insulin sensi-
tivity and associated peripheral glucose uptake.91,93,96,97 SGLT2
inhibition also appears to directly affect pancreatic a-cells,
leading to an increase of glucagon and subsequent (hepatic)
gluconeogenesis.91,96,98
Non-glycaemic effects of sodium–
glucose cotransporter 2 inhibition
Classical CV risk factors include age, smoking, hyperglycaemia,
hypertension, dyslipidaemia, obesity (especially visceral) with sub-
clinical inflammation, and endothelial dysfunction—conditions
which are often interrelated (Figure 1).4,99,100 Intensive glycaemic
control with current therapies may alter several risk factors such
as blood pressure and dyslipidaemia but negatively influence other
risk factors such as body weight. Furthermore, the CV mortality and
all-cause mortality are generally not decreased, indicating glycaemic
control alone is not enough to tackle the problem of CV risk in dia-
betic patients.4,101,102 As mentioned above, trials have suggested
that SGLT2 inhibitors are able to lower HbA1c and fasting blood
glucose with low risk of hypoglycaemia or serious events. Here,
the impact on CV risk factors is described.
Body weight
Body weight is a central factor in diabetes: 85% of all T2DM patients
are overweight, and body weight increases with age, also in T1DM
patients.3,7,99,103 – 105 Obesity and metabolic syndrome are estab-
lished independent predictors for CVD.100 Risk of having a stroke
or CAD doubles when diabetic patients are also overweight.3
SGLT2 inhibition may lead to a decrease in body weight by
depletion of plasma volume, or by caloric loss of glucose via urine.
Theoretically, SGLT2 inhibition by 20–25% could lead to loss
of 60–80 g of glucose per day, which would equal 260–
320 kcal.12,22,39 Pre-clinical research has shown that SGLT2 inhib-
ition is associated with a decrease (or sometimes no change) in
body weight, which was often paired with an increase in caloric in-
take.55,82,95,106 This could indicate that the increased caloric intake is
compensated by increased energy expenditure in response to
SGLT2 inhibitors in animal models. Furthermore, a reduction of
SGLT2 inhibition and the heart 247
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Table 2 Selection of clinical trials with sodium–glucose cotransporter 2 inhibition as a treatment for diabetes
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Dapagliflozin Placebo
Low dose–high dose
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Low dose–high dose

















































676 18 weeks Reduction in HbA1c 73
Empagliflozin Placebo
Low dose–high dose
7020 3 years Death from cardiovascular causes,
nonfatal myocardial infarction or
nonfatal stroke
74
Empagliflozin Placebo 267 52 weeks Change in HbA1c from baseline Recruiting, results in 2017
SGLT-2 inhibitors DPP-1 inhibitors
Glimepiride
100 6 months Effects of treatment on the nominal
change in arterial stiffness from
baseline
Recruiting, results in 2017
(cardiovascular effects)
Dapagliflozin (DEFINE-HF) Placebo 250 12 weeks Difference in the average reduction of
NTproBNP
Not yet recruiting, results
in 2017
Dapagliflozin (REFORM) Placebo 58 Safety/efficacy
study
Change in LV systolic- or diastolic
volume




440 52 weeks Mean change in HbA1c from baseline Recruiting, results in 2019
Continued
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body weight was related to a reduction in (epididymal) fat
tissue.44,82
Clinical data have revealed a reduction of 2.2–3.3 kg body
weight after 18–24 weeks of dapagliflozin treatment versus 20.9
to 1.55 kg weight gain in placebo-treated groups, depending on the
initial body weight.59,60,62,63,80,81 This drop in body weight was sus-
tained but did not decrease further during a follow-up period of 52
weeks.61 Empagliflozin, ipragliflozin, and canagliflozin showed a com-
parable dose-dependent weight reduction, combined with a reduc-
tion in waist circumference.71,73,84,86,87,89 Combination therapy
seemed to be beneficial in terms of the amount of weight loss.89
Body weight reduction was also achieved on top of (inadequately
controlled) insulin treatment, where the body weight gain due to
insulin was not only inhibited, but in fact significantly reduced: 4.3–
4.5 kg after 12 weeks.77,90
A study of body composition showed a numerically larger decrease
in fat tissue mass compared with lean tissue mass in dapagliflozin-
treated patients, in comparison to placebo-treated patients after
12 weeks, and even more after 24 weeks.107 Additionally, it was ob-
served that there was a shift from glucose oxidation to lipid oxidation
in empagliflozin-treated patients,60 indicating that the decrease in
body weight appears to be associated with a loss of fat mass.
Others have investigated if intrusion of renal reabsorption would
alter the uptake of electrolytes, which could consequently influence
the bone mineral density, and eventually body weight.107 Generally,
no changes were observed in electrolytes concentrations, with the
exception of small (and arguably physiologically irrelevant) increases
in serum magnesium and phosphate.60,63,76 Bone density was re-
duced in femoral and hip and increased in the spine, leading to no
difference in bone turnover, and therefore no influence on overall
body weight without an increased rate of bone fractures.107
Energy expenditure, measured by respiratory rate, heart rate, and
body temperature, was unaffected by SGLT2 inhibition.61,92 Long-
term stagnation of body weight could therefore be explained by
an increase in caloric intake.60 This would correspond with pre-
clinical data where nearly all animals showed an increase in chow
consumption.
Blood pressure
Hypertension is a very common co-morbidity of diabetes.108
It may arise in diabetic patients due to sodium retention, to
hyperinsulinaemia and insulin resistance, and to baroreceptor im-
pairment leading to sympathetic overdrive.109 – 111 Hypertension is
one of the main drivers of micro- and macrovascular complications
by promoting endothelial dysfunction and decreased nitric oxide
production.108,109 Therefore, blood pressure reduction is an im-
portant element of vascular protection in diabetes mellitus.78
SGLT2 inhibition may lead to a decrease in blood pressure by the
diuretic effect of glycosuria and increased sodium excretion through
the inhibition of Na+ reabsorption, which is coupled to glucose
(Figure 2).2,76,88 One study done by Osorio et al. showed that
SGLT inhibition with phlorizin prevented the development of
hypertension in rats with STZ-induced diabetes fed a normal diet
or a high-salt diet.40 This may indicate a role of SGLT in the devel-
opment of hypertension, by lowering excessive sodium and water
reabsorption.
The combination of SGLT2 inhibition with metformin led to an
average decrease in SBP of 4 mmHg, while diastolic blood pres-
sure decreased by 0–1.5 mmHg.59,61,67,71,73,84,112 Combination
therapy of a SGLT2 inhibitor with insulin effectively decreases blood
pressure to a greater extent compared with metformin, while
monotherapy with SGLT2 inhibition lowered blood pressure to a
smaller extent.60,63,67,77,85
By looking at diastolic blood pressure, heart rate, and systolic
blood pressure in several clinical trials, Chilton et al. calculated
the index for ambulatory stiffness, a strong indicator for macrovas-
cular disease. They found a favourable effect of empagliflozin on
markers for arterial stiffness.113 Additionally, empagliflozin treat-
ment has been shown to decrease arterial stiffness and may also pre-
vent the development of endothelial dysfunction in T1DM.75,114
A meta-analysis showed a decrease in systolic blood pressure,
ranging from 3.6 to 6.6 mmHg.78– 80 This effect remained constant
after a follow-up of 52–72 weeks.67,71,89 These results indicate
that SGLT2 inhibition might confer sustained blood pressure lower-
ing effects. Of note, there was no increase in safety issues such as
hypotension or dehydration found in these studies.86,89,95,115
Uric acid
Serum uric acid levels have consistently been linked to CVD.116,117
Excessive amounts of uric acid [over 6–7 mg/dL (360–416 mmol/L)]
may alter endothelial function and stimulate smooth muscle cell
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Continued
Compound Comparator n Duration Primary endpoint References
Empagliflozin
(JARDIANCEw)
Low dose–high dose 6000 156 weeks Incidence of adverse drug reactions Recruiting, results in 2020
T1DM
Empagliflozin Placebo 42 8 weeks Change in GFR 75
Empagliflozin (EASE-3) Placebo 960 52 weeks Mean change in HbA1c from baseline Recruiting, results in 2017




768 52 weeks Mean change in HbA1c from baseline Recruiting, results in 2017
n, number of patients; T2DM, type 2 diabetes mellitus; T1DM, type 1 diabetes mellitus; HF, heart failure; LV, left ventricular.
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proliferation and the release of pro-inflammatory cytokines.117,118
Serum uric acid is also strongly related to diabetic nephropathy in
T1DM and T2DM patients. A decrease in serum uric acid has
been described in response to SGLT2 inhibition.74,76,86 These de-
clines were apparent when SGLT2 inhibitors were tested both
when applied as mono- and as add-on therapy, ranging from a de-
crease of 21–51 mmol/L, independent of the drug and treatment
time.59–63,67 In contrast, several other oral antidiabetic treatments
were related to an increase in uric acid of 16–20 mmol/L.61,63
SGLT2 inhibition may affect the level of serum uric acid due to
the osmotic gradient of glycosuria. Uric acid is secreted from the
tubular cells by glucose activation of the glucose–uric acid trans-
porter (GLUT9b). An increase in glucose might lead to an increase
in uric acid excretion and thus a decrease in serum uric acid.118 Col-
lectively, the effects of SGLT2 inhibition on uric acid might be bene-
ficial in T2DM patients, while the effects in T1DM patients remain
unknown.
Haematocrit
Haematocrit, a measure for haemoglobin, has been related to
CVD.119 High haematocrit values are related to increases in blood
viscosity, cardiac work, left ventricular hypertrophy, and throm-
bosis.79,119– 121 The risk for all-cause mortality and cardiac and infec-
tious mortality rises with increasing percentages of haematocrit in
diabetic patients.119
In response to SGLT2 inhibition with dapagliflozin or empagliflo-
zin, haematocrit would increase by 1–3.5%, and with canagliflozin
by 5.7–6.4%.59,61 – 63,67,71,84 Placebo treatment led to a 1–2% de-
crease in haematocrit.59,67,71 Increased values of haematocrit are
most probably explained by the volume depletion of SGLT2 inhib-
ition.60 It is unclear whether this change is clinically relevant. Of
note, there was no association found between SGLT2 inhibition
and thrombosis.79
Effect of sodium–glucose cotransporter 2
inhibition on the kidney: nephropathy and
kidney disease
Because of the substantial effects of SGLT2 inhibition on the
kidney, renal markers of diabetic nephropathy and kidney disease
are separately discussed. Renal function is also highly predictable
for severity of atherosclerotic disease.122 Diabetic nephropathy is
caused by glomerular and tubular injury, exemplified by hyper-
trophy of the basement membrane, tubules, epithelial
mesenchymal transition, glycogen accumulation, and interstitial
inflammation.118 This is accompanied by (micro) albuminuria and a
decline in GFR. By definition, nephropathy is characterized by a
GFR of ,60 mL/min and/or by albuminuria of .300 mg/24 h.61,122
It has been suggested that SGLT2 inhibition may preserve renal func-
tion in both T1DM patients and T2DM patients. However, potential
nephrotoxicity due to increased glucose exposure needs to be
investigated.2
Generally, diabetic patients exhibit an increased GFR during early
disease, so called hyperfiltration. Theoretically, this could be re-
duced by SGLT2 inhibition, due to a decreased reabsorption of so-
dium and glucose, and thereby initiating the tubuloglomerular
feedback mechanism to reduce the filtration rate.24,106 Pre-clinical
studies have showed that SGLT2 inhibition prevented the diabetic
growth of the kidney and decreased glomerular size, albuminuria,
and inflammation.37,55,115 Additionally, gene expression of inflam-
matory markers was decreased in the glomerulus and cortex,
macrophage infiltration was decreased, and oxidative stress in the
tubular cells was significantly down-regulated.95
Clinical data of SGLT2 inhibition have shown a small decrease in
GFR of 0.5 mL/min/1.73 m22 after 18 weeks of dapagliflozin treat-
ment and a decrease of 2–3.8 mL/min/1.73 m22 after 104 weeks of
canagliflozin treatment. However, this was in both cases more pro-
nounced in the group receiving a reference drug (decrease of 5–
6 mL/min/1.73 m22 with glimepiride or glipizide, respectively).61,87
Other studies showed no difference in GFR.62,71,84 A meta-analysis
concluded that SGLT2 inhibition has no major effect on GFR,76 or a
small decrease in GFR without a change in albuminuria.79 An explan-
ation could be that clinical trials usually select for patients with rela-
tively preserved renal function at the commencement of the study,
and that the duration of these studies is not long enough to properly
study the (inhibition of the) development of renal disease. The most
recent trial with a follow-up of 3 years showed a lower incidence of
patients with acute renal failure in empagliflozin-treated groups
compared with placebo groups,74 which may hint towards a pro-
tective effect of SGLT2 inhibition on renal function.
Sodium–glucose cotransporter 2
inhibition in the diabetic heart
Even though there is a negligible expression of the SGLT2 transport-
er in the myocardium,123,124 inhibitors may have an influence on the
cardiac tissue via other mechanisms.
Collagen accumulation and sensitivity to catecholamines may
be altered in the diabetic heart, as well as destructive neuropathy
affecting sympathetic and parasympathetic nerve endings leading
to altered electromechanical conduction. Indeed, patients with
diabetes are more susceptible to spontaneous arrhythmias and
third-degree AV block.125,126 Myocytes isolated from STZ-induced
diabetic rats have amplitude shortening and reduction of the calcium
transient amplitude in response to dapagliflozin in comparison with
myocytes from control rats, indicating a decrease in myocyte
contraction force in response to SGLT2 inhibitor. However, this
presumably negative inotropic effect of dapagliflozin has been mea-
sured only after short-term exposure, indicating the development of
tolerance to the effects of dapagliflozin.127 There was no effect of
dapagliflozin found on QT/QT intervals of healthy patients (a meas-
ure to evaluate ventricular repolarization of a drug).128
A recent study investigated the influence of empagliflozin on
the diabetic heart by looking at fibrosis, coronary arterial thickening,
inflammation, and oxidative stress in the hearts of diabetic obese
db/db mice. The authors showed that 10 weeks of treatment signifi-
cantly reduced cardiac interstitial fibrosis, perivascular fibrosis, cor-
onary arterial thickening, cardiac interstitial macrophage infiltration,
and cardiac superoxide levels. Furthermore, endothelial function
improved, indicated by an enhanced vasodilatory response to
acetylcholine.129 These results may indicate a cardioprotective func-
tion of SGLT2 inhibition in diabetic patients. Thus far, the effects of
SGLT2 inhibition on neuropathy or retinopathy have not been
established.
250 A.E. de Leeuw and R.A. de Boer
Downloaded from https://academic.oup.com/ehjcvp/article-abstract/2/4/244/2197138
by University of Groningen user




The effects of SGLT2 inhibition on CV outcome may be assessed
by investigating diabetic complications, both in the small vessels
and in larger vessels translating into CV events. Vascular dysfunction
and endothelial damage in the smaller vessels are often caused by
hyperglycaemia due to non-enzymatic glycation, which leads to
oxidative stress, which can be measured by an increase in reactive
oxygen species.6,109,130,131 Macrovascular complications such as
myocardial infarction, stroke, and peripheral vascular disease are
usually caused by the acceleration of atherosclerosis.100,109,132 It
has been shown that intensive glycaemic control with sulfonylurea
derivatives, insulin, dietary restriction, or metformin leads to a
24% decrease in microvascular disease and a 33% decreased risk
of myocardial infarction after 10 years.1,4,133
How does SGLT2 inhibition compare?
Sodium–glucose cotransporter 2
inhibition and prevention of major
cardiovascular events
Most clinical studies testing SGLT2 inhibition reported no or a low
incidence of serious adverse events, which could be due to the size
and duration of these trials,62,63,71,92,93 and the number was numer-
ically equal to control patients.86,87 Meta-analyses suggested benefit
of SGLT2 inhibition on CV function compared with placebo,
although this was found to be equal when compared with other anti-
diabetic therapies.78,79 However, a recent randomized, placebo-
controlled trial of Zinman et al., the EMPA-REG study, prospectively
evaluated if SGLT2 inhibition could reduce hard CV endpoints.74
They tested the value of empagliflozin in 7020 patients with
T2DM, and followed long term (median follow-up of 3.1 years).
Primary outcome was a composite of CV mortality, non-fatal
myocadial infarction (MI), and non-fatal stroke. Treatment with em-
pagliflozin resulted in a decreased risk for the primary outcome
compared with placebo patients [hazard ratio (HR) 0.85; 95% CI
0.74–0.99; P ¼ 0.04 for superiority). There were no clear differ-
ences in non-fatal MI and non-fatal stroke. But empagliflozin signifi-
cantly reduced the CV mortality (38% relative risk reduction) and
all-cause mortality (32% relative risk reduction). Interestingly, hospi-
talization due to heart failure was also reduced. In a sub-study of
EMPA-REG, Fitchett et al. specifically investigated the impact of em-
pagliflozin treatment on heart failure. Their results showed a sub-
stantial decrease in heart failure (HR 0.65; 95% CI 0.50–0.85) and
CV mortality (HR 0.65; 95% CI 0.49–0.77) in T2DM patients with
and without baseline heart failure.74,134 Although up until now we
have only one large RCT, the results of EMPA-REG were welcomed
and have prompted several more studies that will test the hypoth-
esis that SGL2 inhibitors may effectively reduce hard CV endpoints.
The question remains whether the beneficial effects of SGLT2 in-
hibition on outcome is related to the strong diuretic effect or
through other mechanisms of action, and future studies should
provide more mechanistic detail. Although these results need to
be validated, the current studies provide strong suggestion that
SGLT2 inhibitors may reduce the incidence of CV events and also,
in particular, new onset heart failure.
Safety
So far, SGLT2 inhibition and glycosuria appear well tolerated and
have not been associated with excessive side effects with a low
chance at developing hypoglycaemia.79,80,83,135 But few concerns
exist, such as a potentially deleterious effects on kidney function
or excessive water loss and dehydration.21,39 Glucose excretion
via urine increases the risk of genitourinary infections, usually pre-
sented as genital infections (4% increase compared with placebo)
and sometimes shown in urinary tract infections (1% increase
compared with placebo).53 These infections were generally con-
sidered non-severe and could easily be treated with antibiotic treat-
ment.12,39,53 A potentially disturbing tendency towards an increased
incidence of breast and bladder cancer has been reported—clearly
this needs to be investigated more intensively in clinical trials.2,53 Re-
assuringly, animal studies with doses up to 100 times the clinical do-
sages did not show carcinogenic mutagenesis.22
Concerns might be the binding to SGLT1 or other locations of
SGLT2 expression, and its indirect effects on vital tissues, such as
brain. In addition, studies have shown that glucose absorption might
be delayed during SGLT2 inhibition.85 More long-term studies will
be required to reveal other possible side effects.
Conclusion
SGLT2 inhibition is the most recent addendum to the arsenal of oral
antidiabetic agents. Data thus far suggest it to be a safe and tolerable
intervention, which reduces hyperglycaemia by urinary glucose ex-
cretion. SGTL2 inhibition can be prescribed as a monotherapy, but
is easily combined with other interventions, where it further
reduces target values of inadequately controlled patients. The ben-
efits of this class of drugs may be that they function in an insulin-
independent manner by which they reduce HbA1c values and
plasma glucose and improve insulin sensitivity and the functioning
of b-cells. Furthermore, it has a favourable CV profile regarding de-
creases in blood pressure and body weight, which are maintained
over a prolonged period of time.74 A reduction in uric acid may re-
duce the risk of developing atherosclerosis and associated diseases,
as well as the small shift in the lipid balance. Pre-clinical data have
suggested that the cardioprotective effect of SGLT2 inhibition
may be conferred by the reduction of ROS and cardiac interstitial
fibrosis.129 A large trial indeed suggested that all-cause mortality
and new onset heart failure were reduced in patients using SGLT2
inhibitors,74 and that diabetic patients at high CV risk were better
protected against heart failure with SGLT2 inhibition compared
with placebo groups.134 The most common side effect is genito-
urinary infection, which is however easily treated.
Several additional studies are needed before we can recommend
SGTL2 inhibition for a wide array of patients. Currently, many stud-
ies are recruiting to investigate the effect of SGLT2 inhibition in pa-
tients with T1DM (Table 2). Second, another area of uncertainty is if
SGLT2 inhibition would be suitable for patients with a compromised
glomerular filtration12,18,53 and what the impact of the high expos-
ure to sodium and glucose in the kidney could be in the long term.88
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However, no major effects on albumin secretion or GFR have been
observed, and possible protective effects have been reported.74
Third, with respect to its presumed organ protective effects, it
would be interesting to know if SGLT2 inhibition could be a bene-
ficial add-on therapy in diabetic patients who have to recover from
earlier CV events. Given the very promising and encouraging results
thus far, SGLT2 inhibition has the potency to become the drug of
choice for patients suffering from diabetes with a high risk at heart
disease.
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